International law · reviewed July 22, 2026
International rules are not one system. Australia has a narrow authorized-psychiatrist pathway for an unapproved psilocybine medicine; the Czech Republic has an enacted but tightly controlled medical framework whose practical rollout is still limited; Germany has a current named compassionate-use program; and Dutch law prohibits hallucinogenic mushroom fruiting bodies while treating magic truffles differently.
Status in brief
Authorized psychiatrists may access an unapproved psilocybine medicine for treatment-resistant depression under federal and state or territory controls. The pathway does not create retail or take-home access, home cultivation, or general personal-use access to mushrooms.
Limited therapeutic use became legally possible on January 1, 2026 in specified healthcare settings. The latest official availability statement said patient applications and waiting-list registration were not yet open.
Psilocybin remains a non-marketable narcotic. BfArM lists a named compassionate-use program for treatment-resistant depression from June 18, 2026 through June 17, 2027.
Hallucinogenic mushroom fruiting bodies remain prohibited. Magic truffles or sclerotia fall outside the Opium Act under a 2026 Supreme Court ruling, but that is not medical approval or general mushroom legalization.
Boundary
Research, a clinical trial, compassionate use, a narrow prescription exception, or lawful sale of one product form does not create general personal-use legality, home cultivation, retail sales, dispensary access, ordinary medical access, or permission to import into another country.
Product-format context
Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.
Educational information only. Not medical advice. 21+ only.
Regional guides